ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
119.662,38
0,08%
S&P 500
5.431,60
-0,04%
US Dollar vs BRL
5,37632
0,48%
Bitcoin
66.181,98
-0,69%
Brent Oil
82,575
0,55%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Atara Biotherapeutics Inc (ATRA)

  7. Atara Biotherapeutics Inc (ATRA) Notícias

ATRA

Atara Biotherapeutics (ATRA)

Atara Biotherapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ATRA
DataHoraFonteTítuloCódigoCompanhia
11/06/202418:06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ATRAAtara Biotherapeutics Inc
07/06/202417:01Business WireAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATRAAtara Biotherapeutics Inc
05/06/202417:01Business WireAtara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
29/05/202417:01Business WireAtara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual MeetingNASDAQ:ATRAAtara Biotherapeutics Inc
22/05/202419:18Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:ATRAAtara Biotherapeutics Inc
20/05/202421:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
20/05/202410:25Business WireAtara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDANASDAQ:ATRAAtara Biotherapeutics Inc
16/05/202422:15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
10/05/202417:30Edgar (US Regulatory)Form DEFR14A - Revised definitive proxy soliciting materialsNASDAQ:ATRAAtara Biotherapeutics Inc
09/05/202417:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATRAAtara Biotherapeutics Inc
09/05/202417:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATRAAtara Biotherapeutics Inc
09/05/202417:01Business WireAtara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational ProgressNASDAQ:ATRAAtara Biotherapeutics Inc
28/03/202409:30Business WireAtara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational ProgressNASDAQ:ATRAAtara Biotherapeutics Inc
29/02/202411:05Business WireAtara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T TherapyNASDAQ:ATRAAtara Biotherapeutics Inc
28/02/202418:30Business WireAtara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
14/02/202411:00Business WireAtara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus NephritisNASDAQ:ATRAAtara Biotherapeutics Inc
01/02/202404:25PR Newswire (US)Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet OncologyNASDAQ:ATRAAtara Biotherapeutics Inc
09/01/202418:28Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATRAAtara Biotherapeutics Inc
08/01/202411:00Business WireAtara Biotherapeutics Announces $15 Million Registered Direct OfferingNASDAQ:ATRAAtara Biotherapeutics Inc
08/01/202410:00Business WireAtara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
04/01/202418:01Business WireAtara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
20/12/202318:01Business WireAtara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre LaboratoriesNASDAQ:ATRAAtara Biotherapeutics Inc
11/12/202314:00Business WireAtara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual MeetingNASDAQ:ATRAAtara Biotherapeutics Inc
01/12/202318:01Business WireAtara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATRAAtara Biotherapeutics Inc
29/11/202320:05Business WireAtara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023NASDAQ:ATRAAtara Biotherapeutics Inc
22/11/202318:01Business WireAtara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
17/11/202318:31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ATRAAtara Biotherapeutics Inc
14/11/202302:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATRAAtara Biotherapeutics Inc
10/11/202318:01Business WireAtara Biotherapeutics To Participate at the Stifel Healthcare ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
08/11/202319:35Business WireAtara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple SclerosisNASDAQ:ATRAAtara Biotherapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ATRA

Seu Histórico Recente

BOV
COGN3
COGNA ON
BOV
HBOR3
HELBOR ON
BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados